SA
NVO

SRH Advisors’s Novo Nordisk NVO Stock Holding History

SRH Advisors’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$29.4K Hold
800
– – 0.01% 162
2025
Q4 		$40.7K Hold
800
– – 0.01% 137
2025
Q3 		$44.4K Buy
+800
New +$46.8K 0.01% 134

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

SRH Advisors's NVO Position: Q1 2026 in Review

SRH Advisors held its Novo Nordisk (NVO) position steady in Q1 2026 at 800 shares worth $29.4K. The position accounts for 0.01% of the portfolio, ranked #162.

SRH Advisors first reported a position in NVO in Q3 2025 and has held it in 3 quarters since. The position peaked at $44.4K in Q3 2025. 1,271 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • SRH Advisors held 800 shares of Novo Nordisk worth $29.4K as of Q1 2026.
  • SRH Advisors left its Novo Nordisk share count unchanged in Q1 2026.
  • Novo Nordisk made up 0.01% of SRH Advisors's portfolio in Q1 2026, its #162 holding.
  • SRH Advisors first reported a position in Novo Nordisk in Q3 2025 and has held it in 3 quarters since.
  • SRH Advisors's Novo Nordisk position peaked at $44.4K in Q3 2025.
  • 1,271 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on SRH Advisors's 13F filing for Q1 2026, filed 29 Apr 2026.